PPARA and liver disorder: These fatty acid ethanolamides then act via receptors including PPARα, GPR119, and GPR55 to regulate cholesterol and triglyceride levels and promote the resolution of inflammation, thereby protecting against cardiometabolic diseases including metabolic-dysfunction associated steatotic liver disease and atherosclerotic cardiovascular disease.